<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03033030</url>
  </required_header>
  <id_info>
    <org_study_id>102REG2016</org_study_id>
    <nct_id>NCT03033030</nct_id>
  </id_info>
  <brief_title>Tomosynthesis (TS) or Ultrasound (US) in Mammography-negative Dense Breasts (TOMUS). National Multicenter Trial</brief_title>
  <acronym>TOMUS</acronym>
  <official_title>Tomosynthesis (TS) or Ultrasound (US) in Mammography-negative Dense Breasts (TOMUS). National Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Genova</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Genova</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Breast cancer remains a worldwide big killer with a rate of deaths compared with newly&#xD;
      diagnosed cases not lower than 20%. Mammography is the primary imaging modality for the early&#xD;
      detection of clinically occult breast cancer. Mammography is established as the primary&#xD;
      investigation for population-based breast cancer screening. Advances in mammographic&#xD;
      technique regarding both hardware and software applications are still not sufficient to&#xD;
      overcome mammography's limitation with regard to both sensitivity and specificity. Depending&#xD;
      on several factors, such as age and breast density, mammography screening is associated with&#xD;
      a false-negative rate of 10-20 %.&#xD;
&#xD;
      Digital Breast Tomosynthesis (TS) is a novel technique that is able to study the breast using&#xD;
      3D reconstructions of the tissue from multiple low-dose digital mammographic images acquired&#xD;
      in several planes in a 15 to 50 degree angle. This process aims at a increasing the number of&#xD;
      lesion visible due to the reduction of overlapping breast tissue.&#xD;
&#xD;
      In TS, to overcome these limitations, a digital mammography (DM) unit is modified to allow&#xD;
      the X-ray tube to move through a proscribed arc of excursion acquiring a fixed number of&#xD;
      discrete projection images while the breast remains in compression. The individual projection&#xD;
      images are extremely low in dose, so the composite dose incurred during a TS acquisition may&#xD;
      be similar to that of a standard 2D mammography. The radiologically dense breasts are&#xD;
      associated with decreased sensitivity of mammography, both in the clinical and screening&#xD;
      setting as well as its established association with breast cancer risk. The systematic&#xD;
      application of ultrasound (US) in women with radiologically dense breasts and negative&#xD;
      mammogram has been shown to be associated with an additional cancer detection rate [7,8,9].&#xD;
      Incremental ultrasound detection of cancer may be considered in the range of 0.27% to 0.52%&#xD;
      of ultrasound-screened women in different density categories [10]. In addition, the main&#xD;
      limitation of US in breast screening is represented by false- positive findings. These&#xD;
      findings result in additional investigation or unnecessary surgical biopsy [10].&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Breast cancer remains a worldwide big killer with a rate of deaths compared with newly&#xD;
      diagnosed cases not lower than 20%. Mammography is the primary imaging modality for the early&#xD;
      detection of clinically occult breast cancer. Mammography is established as the primary&#xD;
      investigation for population-based breast cancer screening. Advances in mammographic&#xD;
      technique regarding both hardware and software applications are still not sufficient to&#xD;
      overcome mammography's limitation with regard to both sensitivity and specificity. Depending&#xD;
      on several factors, such as age and breast density, mammography screening is associated with&#xD;
      a false-negative rate of 10-20 %.&#xD;
&#xD;
      Digital Breast Tomosynthesis (TS) is a novel technique that is able to study the breast using&#xD;
      3D reconstructions of the tissue from multiple low-dose digital mammographic images acquired&#xD;
      in several planes in a 15 to 50 degree angle. This process aims at a increasing the number of&#xD;
      lesion visible due to the reduction of overlapping breast tissue.&#xD;
&#xD;
      In TS, to overcome these limitations, a digital mammography (DM) unit is modified to allow&#xD;
      the X-ray tube to move through a proscribed arc of excursion acquiring a fixed number of&#xD;
      discrete projection images while the breast remains in compression. The individual projection&#xD;
      images are extremely low in dose, so the composite dose incurred during a TS acquisition may&#xD;
      be similar to that of a standard 2D mammography. The radiologically dense breasts are&#xD;
      associated with decreased sensitivity of mammography, both in the clinical and screening&#xD;
      setting as well as its established association with breast cancer risk. The systematic&#xD;
      application of ultrasound (US) in women with radiologically dense breasts and negative&#xD;
      mammogram has been shown to be associated with an additional cancer detection rate.&#xD;
      Incremental ultrasound detection of cancer may be considered in the range of 0.27% to 0.52%&#xD;
      of ultrasound-screened women in different density categories [10]. In addition, the main&#xD;
      limitation of US in breast screening is represented by false- positive findings. These&#xD;
      findings result in additional investigation or unnecessary surgical biopsy.&#xD;
&#xD;
      The study aims to demonstrate at least statistical equivalence, or non-significant difference&#xD;
      between TS and US in women with dense breasts.&#xD;
&#xD;
      If the equivalence between TS and US will be demonstrated, US may be substituted by TS with&#xD;
      great benefits for the patients and for the healthcare resources we aim to:&#xD;
&#xD;
        1. Assess if TS may detect additional cancers in dense breasts that approximate US&#xD;
           detection capability but with less false positive findings than US.&#xD;
&#xD;
        2. If TS detects new cancers in dense breasts similarly to US (approximate rate or&#xD;
           marginally lower rate), evaluate the true positive/false positive ratio.&#xD;
&#xD;
        3. Cost-analysis. In case of less false positives detected by TS, the TP/ FP trade-off&#xD;
           might be strongly in favour of TS with a great potential of costs reduction.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">February 2014</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incremental Cancer Detection Rate or Area Under the Curve</measure>
    <time_frame>2 years</time_frame>
    <description>The study aims to demonstrate at least statistical equivalence, or non-significant difference between TS and US in women with dense breasts.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TP/FP rate</measure>
    <time_frame>2 years</time_frame>
    <description>If the equivalence between TS and US will be demonstrated, US may be substituted by TS with great benefits for the patients and for the healthcare resources we aim to:&#xD;
Assess if TS may detect additional cancers in dense breasts that approximate US detection capability but with less false positive findings than US.&#xD;
If TS detects new cancers in dense breasts similarly to US (approximate rate or marginally lower rate), evaluate the true positive/false positive ratio.&#xD;
Cost-analysis. In case of less false positives detected by TS, the TP/ FP trade-off might be strongly in favour of TS with a great potential of costs reduction.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">8000</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Tomosynthesis</arm_group_label>
    <description>Patients undergoing Digital Breast Tomosynthesis</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Ultrasound</intervention_name>
    <description>Ultrasound examination</description>
    <arm_group_label>Tomosynthesis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women who undergo breast TS and Mammography&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Asymptomatic subjects &lt;50 years of age presenting for mammography, with the exception&#xD;
             of those that, on previous mammograms are found to have breast density BI- RADS D1-2.&#xD;
&#xD;
          -  Asymptomatic subjects â‰¥ 50 years of age who request mammography and have breast&#xD;
             density BI-RADS 3-4.&#xD;
&#xD;
          -  Written Informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant and breast feeding women&#xD;
&#xD;
          -  Unable to tolerate breast compression&#xD;
&#xD;
          -  Breast implants&#xD;
&#xD;
          -  Unable to understand or execute written informed consent&#xD;
&#xD;
          -  Unable or unwilling to agree to follow-up during observation period&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UNIGE</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto S Tagliafico, MD</last_name>
      <phone>+390103637873</phone>
      <email>alberto.tagliafico@unige.it</email>
    </contact>
    <investigator>
      <last_name>Alberto S Tagliafico, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>January 24, 2017</study_first_submitted>
  <study_first_submitted_qc>January 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2017</study_first_posted>
  <last_update_submitted>January 25, 2017</last_update_submitted>
  <last_update_submitted_qc>January 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Genova</investigator_affiliation>
    <investigator_full_name>Alberto Tagliafico</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Ultrasound</keyword>
  <keyword>Digital Breast Tomosynthesis</keyword>
  <keyword>Cancer Detection rate</keyword>
  <keyword>Sensitivity</keyword>
  <keyword>Specificity</keyword>
  <keyword>Breast density</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

